Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Novo Nordisk Executive Compensation: A Picture of Modesty (Except for the Car Expenses)
- Novo Nordisk's annual report is out and it contains some interesting stuff on senior management compensation. CEO Lars Rebien Sørensen received total compensation of DKK10.8 million (about $1.8 million). That was modest compared to his counterparts at American companies. (At Eli Lilly, CEO John Lechleiter got $13...
- Blog posts 2009-02-17
- Novo Nordisk's Liraglutide Logos Leak Out Before Approval
- UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here. Novo Nordisk's new diabetes drug, liraglutide, isn't approved by the...
- Blog posts 2008-12-11
- Novo Nordisk Expands R&D Presence in China with New Manufacturing Plant
- ChinaBio Today submits: Novo Nordisk NVO will invest almost $400 million to build a very large insulin manufacturing facility in Tianjin. The new facility will function as the company’s primary production site in China and serve the entire Asia Pacific region. The new 22,500 sq. meter plant, which will...
- External links 2008-11-11
Additional Resources
- Pfizer Inc. (Active Pharmaceutical Ingredient Watch).(seeks to terminate license agreement with Novo Nordisk )(Brief Article)
- NOVO NORDISK A/S reports that Pfizer Inc. has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk's portfolio of hormone replacement therapy products, Activella and Vagifem, in the US. In 2002, Novo Nordisk gained a NOVO NORDISK A/S reports that Pfizer...
- Research articles 2003-06-09
- Novo Nordisk acquires enzyme patents and know-how from Showa Denko
- BAGSVAERD, Denmark; TOKYO--BUSINESS WIRE--Oct. 1, 1996--Novo Nordisk and Showa Denko today announced that Novo Nordisk will acquire Showa Denko's patents and know-how related to industrial enzymes in connection with Showa Denko's decision to terminate activities in this field. "This deal will improve Novo Nordisk's position within some...
- Research articles 1996-10-01
- NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes.
- M2 PRESSWIRE-17 August 1998-NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes C1994-98 M2 COMMUNICATIONS LTD RDATE:170898 Novo Nordisk A/S (NYSE:NVO) today announced that the European Commission has approved NovoNorm (repaglinide - Prandin in the...
- Research articles 1998-08-17
- Novo Nordisk gift creates University of Toronto/Banting and Best Diabetes Centre student environment
- TORONTO--BUSINESS WIRE--Oct. 8, 1996--Novo Nordisk A/S (NYSE:NVO) has commemorated the 75th Anniversary of the discovery of insulin and honored the institution that enabled Novo Nordisk to become the world leader in the production of insulin through a gift that will live long into the future. The University...
- Research articles 1996-10-08
- Novo Nordisk files suit against Becton Dickinson
- NEW YORK--BUSINESS WIRE--Dec. 18, 1996--Novo Nordisk A/S (NYSE:NVO) has filed a lawsuit in the U.S. District Court, Southern District of New York against Becton Dickinson and Company. Novo Nordisk alleges in the suit that Becton Dickinson has infringed a Novo Nordisk patent relating to the NovoPenR 1.5...
- Research articles 1996-12-18
- Novo Nordisk Prevails in Sanofi-Aventis Challenge to Levemir(R) -- Up to 24 Hours Duration of Action and Other Claims Upheld
- Novo Nordisk (NYSE: NVO) announced today a victory in a lawsuit in which Sanofi-Aventis sought a preliminary injunction against Novo Nordisk's pre-launch and launch materials for Levemir® (insulin detemir [rDNA origin] injection), Novo Nordisk's new long-acting basal insulin.
- Research articles 2006-06-27
- Aradigm and Novo Nordisk Execute Further Restructuring of Partnership
- Aradigm Corporation (NASDAQ: ARDM) today announced the execution of an agreement further developing the strategic partnership with Novo Nordisk. The agreement is designed to strengthen Novo Nordisk's patent position within the area of inhaled insulin as related products progress towards commercialization and has resulted in a non-dilutive cash infusion to...
- Research articles 2006-07-05
- Roche, Novo Nordisk Link.(Brief Article)
- HOFFMANN-LA Roche and Novo Nordisk have formed a strategic alliance for feed enzymes. The alliance, which is between Roche's vitamins and fine chemicals ... HOFFMANN-LA Roche and Novo Nordisk have formed a strategic alliance for feed enzymes. The alliance, which is between Roche's vitamins...
- Research articles 2000-07-10
- From the Vault: Novo Nordisk's "Captain Novolin" Nightmare
- A reader wrote to me to complain that Pfizer was not a pioneer of drug-based video games, as I asserted its "Viva Cruiser" effort was for Viagra. She said: There was a game that Novo Nordisk put out about 15 years ago to promote their insulin called Captain Novolin....
- Blog posts 2008-09-06
- Novo Nordisk pays R$130mil for Biobras.
- Brazil, Dec 5, 2002 (Gazeta Mercantil/SABI via COMTEX) ABN Amro is to announce the completion of the shares acquisition operation of the Brazilian pharmaceutical company Biobras on behalf of the Danish Novo Nordisk, in a move worth R$130mil, R$55.7mil of which paid to minority...
- Research articles 2002-12-06
- Crucell announces STAR(TM) Research License Agreement with Novo Nordisk A/S
- Leiden, The Netherlands, 16 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STARTM research license agreement for the production of monoclonal antibodies with Bagsvaerd, Denmark-based Novo Nordisk A/S. Novo Nordisk A/S intends to evaluate the STARTM technology using...
- Research articles 2007-01-16
- Novo Nordisk Denmark outsources printing operations to Stralfors AB
- NORDIC BUSINESS REPORT-22 February 2006-Novo Nordisk Denmark outsources printing operations to Stralfors ABC1994-2006 M2 COMMUNICATIONS LTD http://www.m2.com The Swedish information logistics group Stralfors AB said on Tuesday (21 February) that it had agreed to take over Danish pharmaceutical company Novo Nordisk's internal printing operations. The agreement covers 35...
- Research articles 2006-02-22
- Novo Nordisk.(People)(Brief Article)
- * Novo Nordisk has appointed Alan C. Moses associate vice president of medical affairs in the United States. Moses comes to Novo Nordisk from the Joslin Diabetes Center and Joslin Clinic in Boston, where he was chief medical officer and senior vice president for the past five...
- Research articles 2004-06-01
- Jyske Bank, Amagerbanken rate "buy" after Novo Nordisk H1 report
- NORDIC BUSINESS REPORT-6 August 2009-Jyske Bank, Amagerbanken rate "buy" after Novo Nordisk H1 reportC1994-2009 M2 COMMUNICATIONS http://www.m2.com 6 August 2009- Jyske Bank and Amagerbanken maintained their "buy" ratings on Novo Nordisk A/S (CPH: NOVO B) after the Danish pharma company today posted first-half results for 2009. ...
- Research articles 2009-08-06
- US District Court affirms Genentech's request for Preliminary Injunction against Novo Nordisk Growth Hormone
- NEW YORK--BUSINESS WIRE--June 27, 1996--Denmark-based pharmaceutical and biotechnology group Novo Nordisk A/S (NYSE:NVO) issued the following statement in response to a US District Court decision in the ongoing patent litigation between Novo Nordisk and Genentech.
- Research articles 1996-06-27
- NOVO NORDISK.(received approval from FDA for its liquid growth hormone Norditropin)(Brief Article)
- NOVO NORDISK received approval from FDA for its liquid growth hormone Norditropin (somatropin [rDNA origin] injection) in cartridges ... NOVO NORDISK received approval from FDA for its liquid growth hormone Norditropin (somatropin [rDNA origin] injection) in cartridges and an accompanying NordiPen delivery system. Norditropin...
- Research articles 2000-06-26
- Novo Nordisk in $42 MM Insulin Deal.(Brief Article)(Statistical Data Included)
- Novo NORDISK and Lyon, France-based Flamel Technologies have entered into a development and licensing agreement for Basulin, Flamel's long-acting basal insulin product for type I and type II diabetes. The deal is worth roughly $42 million. Un Novo...
- Research articles 1999-12-13
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
